MX2019000546A - Preparacion farmaceutica para la administración oral con uniformidad del contenido mejorada, que comprende perlas de liberación sostenida que continenen hidrocloruro de tamsulosina. - Google Patents

Preparacion farmaceutica para la administración oral con uniformidad del contenido mejorada, que comprende perlas de liberación sostenida que continenen hidrocloruro de tamsulosina.

Info

Publication number
MX2019000546A
MX2019000546A MX2019000546A MX2019000546A MX2019000546A MX 2019000546 A MX2019000546 A MX 2019000546A MX 2019000546 A MX2019000546 A MX 2019000546A MX 2019000546 A MX2019000546 A MX 2019000546A MX 2019000546 A MX2019000546 A MX 2019000546A
Authority
MX
Mexico
Prior art keywords
tamsulosin hydrochloride
extended release
pharmaceutical preparation
oral pharmaceutical
release pellet
Prior art date
Application number
MX2019000546A
Other languages
English (en)
Inventor
Hyun Park Jae
Soo Woo Jong
Cheul Kim Jin
Ii Kim Yong
Hyun Cho Jung
Seo Kim Hyung
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2019000546A publication Critical patent/MX2019000546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una formulación farmacéutica oral que incluye perlas de liberación sostenida que contienen hidrocloruro de tamsulosina y un aditivo farmacéuticamente aceptable, en donde las perlas de liberación sostenida incluyen aproximadamente 50% en peso a aproximadamente 100% en peso de partículas que tienen un tamaño de partícula de aproximadamente 0.50 mm a aproximadamente 0.85 mm y menos de aproximadamente 15% en peso de partículas que tienen un tamaño de partícula menor que aproximadamente 0.50 mm. La formulación farmacéutica oral puede tener una desviación reducida en la tasa de disolución de hidrocloruro de tamsulosina y una uniformidad de contenido mejorada entre las formas de dosificación unitaria y tiene una calidad garantizada debido a la alta reproducibilidad de las formas de dosificación unitaria.
MX2019000546A 2016-07-15 2017-07-14 Preparacion farmaceutica para la administración oral con uniformidad del contenido mejorada, que comprende perlas de liberación sostenida que continenen hidrocloruro de tamsulosina. MX2019000546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160090266 2016-07-15
PCT/KR2017/007586 WO2018012931A1 (ko) 2016-07-15 2017-07-14 함량 균일성이 개선된 탐수로신 염산염 함유 서방성 펠렛을 포함하는 경구용 약제학적 제제

Publications (1)

Publication Number Publication Date
MX2019000546A true MX2019000546A (es) 2019-10-04

Family

ID=60952686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000546A MX2019000546A (es) 2016-07-15 2017-07-14 Preparacion farmaceutica para la administración oral con uniformidad del contenido mejorada, que comprende perlas de liberación sostenida que continenen hidrocloruro de tamsulosina.

Country Status (11)

Country Link
US (1) US20210322319A1 (es)
EP (1) EP3485877A4 (es)
JP (1) JP2019524683A (es)
KR (1) KR102419638B1 (es)
CN (1) CN109475503B (es)
AU (1) AU2017297117A1 (es)
BR (1) BR112019000721A2 (es)
EA (1) EA201892778A1 (es)
MX (1) MX2019000546A (es)
PH (1) PH12019500059A1 (es)
WO (1) WO2018012931A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200078146A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 내산성이 우수한 탐수로신 염산염 함유 제약 조성물 및 이의 제조방법
CN110420179A (zh) * 2019-08-12 2019-11-08 韩育娟 一种炎琥宁干混悬剂及其制备方法
CN114504560A (zh) * 2022-03-10 2022-05-17 河南省人民医院 一种盐酸坦索罗辛缓释制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
KR100570419B1 (ko) * 2004-01-14 2006-04-11 코오롱제약주식회사 염산 탐술로신의 경구 투여용 서방성 펠렛 조성물 및 그제조방법
KR100582350B1 (ko) * 2004-02-17 2006-05-22 한미약품 주식회사 탐수로신 염산염의 경구투여용 조성물 및 이의 서방성과립 제제
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
KR20070044911A (ko) * 2005-10-26 2007-05-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
KR100912680B1 (ko) * 2006-03-16 2009-08-19 (주) 벡스코아 제어 방출 제형
KR100745515B1 (ko) * 2006-04-10 2007-08-02 주식회사 대웅제약 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법
CN101125134B (zh) * 2006-08-16 2010-09-15 常州市第四制药厂有限公司 盐酸坦洛新缓释胶囊及其制备方法
CN101695478B (zh) * 2009-10-23 2012-01-18 江苏大学 盐酸坦索罗辛缓释微丸制剂及其制备方法
KR101686033B1 (ko) * 2010-04-12 2016-12-13 주식회사 대웅제약 탐술로신 또는 이의 약제학적 허용 가능한 염을 유효성분으로 함유하는 장용성 서방형 펠렛부와 속방부로 이루어진 의약 조성물
KR20160100570A (ko) * 2015-02-16 2016-08-24 한미약품 주식회사 탐수로신 염산염 함유 서방성 과립을 포함하는 경구용 약제학적 제제

Also Published As

Publication number Publication date
WO2018012931A1 (ko) 2018-01-18
EP3485877A1 (en) 2019-05-22
KR102419638B1 (ko) 2022-07-12
JP2019524683A (ja) 2019-09-05
BR112019000721A2 (pt) 2019-05-07
US20210322319A1 (en) 2021-10-21
EA201892778A1 (ru) 2019-06-28
EP3485877A4 (en) 2020-02-26
PH12019500059A1 (en) 2019-10-14
CN109475503B (zh) 2021-09-17
AU2017297117A1 (en) 2019-01-24
KR20180008339A (ko) 2018-01-24
CN109475503A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
WO2013130669A8 (en) Pharmaceutical composition and administration thereof
PH12017502326A1 (en) Orodispersible dosage unit containing an estetrol component
MX2019000546A (es) Preparacion farmaceutica para la administración oral con uniformidad del contenido mejorada, que comprende perlas de liberación sostenida que continenen hidrocloruro de tamsulosina.
PH12017502325A1 (en) Orodispersible dosage unit containing an estetrol component
MX2020007554A (es) Formulacion farmaceutica que comprende esomeprazol y bicarbonato de sodio.
PH12017501986A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
MX2020007552A (es) Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.
PH12020500525A1 (en) Manufacturing of pharmaceutical compositions
MX2013007587A (es) Suplementos alimenticios en particulas medicados para animales y metodos de preparacion.
MX2016017131A (es) Composicion novedosa de un producto de confiteria.
MX2019010228A (es) Composición para liberación controlada de sustancias fisiológicamente activas y proceso para su preparación.
MY144613A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
IN2013MU01177A (es)
MX2015011624A (es) Composiciones farmaceuticas secas que comprenden nanoparticulas de agente activo ligadas a particulas portadoras.
WO2017121637A8 (en) Process for the preparation of pellets
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
MX2022013576A (es) Composicion para la liberacion controlada de sustancias fisiologicamente activas y proceso para su preparacion.
PH12019550098A1 (en) Nutritional composition in powder form provided in single serving capsules
MX2017015699A (es) Composiciones de acido diclofenaco.
EP3877379A4 (en) CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION CONTAINING IT
PH12018502103A1 (en) Particle size and distribution of polymer for melt extrusion application
WO2016008401A8 (zh) 一种含多西他赛的药物组合物
BR112017021111A2 (pt) processo para fabricação de misturas de pós secos
CN105461078A (zh) 一种水质改良剂